GlassScriptPhysician profile
Robert D Donaldson
NPI 1053382192
$3,565.60
in general payments reported to CMS, 2019-2025
13 companies · $976 in 2025
The $976 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $352 · 2022: $646 · 2023: $896 · 2024: $696 · 2025: $976.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,567.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $772.86 | 2022-2024 | |
| Novo Nordisk INC | $598.92 | 2022-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $431.44 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $363.22 | 2021-2022 | |
| Amgen INC. | $278.50 | 2023-2025 | Krystexxa, Otezla |
| Lilly USA, LLC | $229.16 | 2022-2025 | Kisunla |
| Glaxosmithkline, LLC. | $213.62 | 2022-2024 | Arexvy |
| Axsome Therapeutics, INC. | $149.12 | 2024 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $121.60 | 2023 | Camzyos |
| Phathom Pharmaceuticals, INC. | $118.39 | 2024 | Voquezna |
| Pfizer INC. | $105.52 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.00 | 2022 | |
| Biogen, INC. | $83.25 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Donaldson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.